Syndicate Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 1.49 M
- Company Age 15 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.90 Cr
- Revenue Growth 29.99%
- Profit Growth 15.10%
- Ebitda 10.97%
- Net Worth 156.88%
- Total Assets 19.59%
About Syndicate Life Sciences
Syndicate Life Sciences Private Limited (SLSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 February 2010 and has a history of 15 years. Its registered office is in Hisar, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.49 M.
The company currently has active open charges totaling ₹3.90 Cr.
Sagar Uppal and Nitin Bhayana serve as directors at the Company.
Company Details
- Location
Hisar, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233HR2010PTC040080
- Company No.
040080
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2010
- Date of AGM
26 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Syndicate Life Sciences Private Limited offer?
Syndicate Life Sciences Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Steroid, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Nutritional Supplements, Ayurvedic,Herbal Products & Medicine, Ayurvedic Tablets.
Who are the key members and board of directors at Syndicate Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Bhayana  | Director | 15-Feb-2010 | Current |
| Sagar Uppal | Director | 15-Feb-2010 | Current |
Financial Performance of Syndicate Life Sciences.
Syndicate Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 29.99% increase. The company also saw a substantial improvement in profitability, with a 15.1% increase in profit. The company's net worth Soared by an impressive increase of 156.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syndicate Life Sciences?
Unlock access to Syndicate Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Elavitra Labs LlpSagar Uppal and Nitin Bhayana are mutual person
- Aricate Formulations Private Limited
Nitin Bhayana is a mutual person
Charges (Loans)
₹38.95 M
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 3.80 Cr
- Canara Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Sep 2020 | Canara Bank | ₹0.95 M | Open |
| 28 May 2014 | Indian Bank | ₹3.80 Cr | Open |
How Many Employees Work at Syndicate Life Sciences?
Unlock and access historical data on people associated with Syndicate Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syndicate Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syndicate Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.